Compositions and methods for potentiating immune activity
AssigneeKumquat Biosciences Inc.
InventorsYi Liu, Jonathan Deane, Amy Strasner, Liansheng Li, Matthew R. Janes, Karen K. Wong, Pingda Ren
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for enhancing immunity (or immune response). The compositions and methods are particularly useful for potentiating immune response of a lymphoid cell. The compositions and methods are also applicable for treating cancer and other diseases.
Claims19
A method of treating cancer in a subject in need thereof, comprising:
- (a) administering systemically a small molecule PTPN2 inhibitor to the subject;
- and (b) administering a second agent or a second therapy concurrently, before, or after step (a), wherein the second agent or the second therapy comprises an amount of lymphoid cell that is sub-therapeutic as ascertained in the absence of the PTPN2 inhibitor, and wherein the lymphoid cell (1) retains expression or activity of PTPN2 prior to being exposed to the small molecule PTPN2 inhibitor, and (2) expresses (i) a chimeric T-cell receptor (TCR) sequence encoding a T-cell receptor fusion protein (TFP) and/or (ii) a chimeric antigen receptor (CAR) sequence encoding a CAR, wherein each of TFP and CAR exhibits specific binding to a tumor antigen, wherein the small molecule exhibits an IC50 of less than or equal to 500 nM for PTPN2 as ascertained in a phosphatase assay utilizing DiFMUP as a substrate.
A composition formulated for administration into a subject comprising a small molecule PTPN2 inhibitor and an amount of modified lymphoid cell that is sub-therapeutic as ascertained in the absence of the PTPN2 inhibitor, wherein the modified lymphoid cell comprises (i) a chimeric T-cell receptor (TCR) sequence encoding a T-cell receptor fusion protein (TFP) and/or (ii) a chimeric antigen receptor (CAR) sequence encoding a CAR, each of TFP and CAR exhibiting specific binding to an antigen;
- and wherein the small molecule PTPN2 inhibitor (a) does not affect editing of the gene encoding PTPN2 or an additional gene operatively linked to PTPN2, and (b) exhibits an IC50 of less than or equal to 500 nM for PTPN2 as ascertained in a phosphatase assay utilizing DiFMUP as a substrate.
Dependencies are inferred from the claim text.